COVID19: Anti-SARS-CoV-2 Antibodies and Infection Severity
Project Number1I01BX005477-01
Contact PI/Project LeaderKAUFMAN, KENNETH M
Awardee OrganizationCINCINNATI VA MEDICAL CENTER RESEARCH
Description
Abstract Text
The new Covid-19 virus is deadly for 0.2% to 4% of people infected, with older men the most severely afflicted
with this scourge, being mortal to ~15% of those infected over 80 years, making the US Veteran population
especially vulnerable. It is critically important to understand the mechanisms of this lethal pathophysiology in
order to design interventions that will save lives. MERS, SARS-CoV, and now the new human Covid-19 mean
that three coronaviruses have threatened to become horrific public health problems for the entire world; this
last and most recent one, Covid-19, has succeeded.
Some of the antibodies formed against this virus appear to accentuate the clinical severity of disease, possibly
making the specific details of the immune response responsible for the demise of many infected patients. We
have had more than two decades of experience as VA Merit supported investigators exploring the antigenic
structure of the lupus autoantigens, leading us to the theory that Epstein-Barr virus causes lupus, which is a
hypothesis now supported by convincing circumstantial evidence. We propose to apply our experience to
exploring the details of the fine antigenic specificity of the anti-Covid-19 antibody response in order to
understand what specific antibodies are dangerous. We propose to explore two hypotheses:
Hypothesis 1. Specific and detailed knowledge of antibody immune responses to Covid-19 will be
useful for elucidating pathogenic mechanisms, predicting disease severity, designing vaccines,
selecting therapeutic plasmas, making patient care decisions, informing population epidemiology,
determining infection dynamics, and choosing individual behaviors in the face of the Covid-19
pandemic.
Hypothesis 2. Anti-Covid-19 antibody fine antigenic specificity will correlate with clinical
manifestations and infection severity.
We propose two aims:
Aim 1. Develop and apply assays to dissect the antigenic fine specificity of antibodies forming against shared
and sub-strain specific Covid-19 antigens in the natural human Covid-19 infection.
Aim 2. Isolate and purify anti-Covid-19 antibodies against the major epitopes and any specific antibodies that
are associated with severe pulmonary disease.
We will use Western blotting, solid phase assays (ELISAs), phage display libraries expressing 30-mer amino
acid peptides, and synthesized overlapping fmoc peptides to fully characterize the fine specificity antibody
response to the Covid-19 virus. We will obtain plasma and serum from Veterans and others which we will
evaluate for correlates with clinical outcome. We will isolate individual specificities and characterize their
properties with respect to type, isotype, glycosylation, and activity. We will perform pseudotype assays on
whole repertoires and individual antibody specificities in BSL2 and test for confirmation with neutralization with
collaborators with BSL3 facilities. From these studies we hope to learn how to identify Veterans who are likely
to have a more severe illness and provide clues for developing approaches that could succeed in ameliorating
infection severity and prevent severe disease.
Public Health Relevance Statement
The VA Health Care System has done a magnificent, under-appreciated job in the COVID-19 pandemic. The
US Veterans served by the health care system are enriched for older men with co-morbid conditions who are
especially vulnerable for serious morbidity and mortality from COVID-19 infection. The problems with serious
lung injury in SARS infections are mediated by specific antibodies, which are enabling a destructive
inflammatory response that makes normal breathing impossible and brings death by suffocation. Antibodies
are proteins that our body makes to defend us against infectious organisms. In this situation some of the
antibodies appear to have the potential to make the infection more deadly instead of defending the infected
Veteran. We propose to identify these specific and dangerous antibodies and then work to understand their
structural characteristics and behavior of these so that we can change the clinical outcome for our many
Veterans at risk of contracting this deadly infection.
No Sub Projects information available for 1I01BX005477-01
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1I01BX005477-01
Patents
No Patents information available for 1I01BX005477-01
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1I01BX005477-01
Clinical Studies
No Clinical Studies information available for 1I01BX005477-01
News and More
Related News Releases
No news release information available for 1I01BX005477-01
History
No Historical information available for 1I01BX005477-01
Similar Projects
No Similar Projects information available for 1I01BX005477-01